|
Parameters
|
Failure
|
Sub-Optimal
|
Optimal
|
|---|
|
Number (%)
|
Number (%)
|
Number (%)
|
|---|
|
Whole population
| | | |
|
Outcome
|
167 (12.39)
|
113 (8.38)
|
1068 (79.23)
|
|
Age
| | | |
|
<60 years
|
80 (10.15)
|
57 (7.23)
|
651 (82.61)
|
|
≥60 years
|
87 (15.54)
|
56 (10.00)
|
417 (74.46)
|
|
Lenalidomide use
| | | |
|
No
|
113 (11.39)
|
78 (7.86)
|
801 (80.75)
|
|
Yes
|
54 (15.17)
|
35 (9.83)
|
267 (75.00)
|
|
Hematological toxicity
| | | |
|
No
|
132 (10.48)
|
106 (8.41)
|
1022 (81.11)
|
|
Yes
|
35 (39.77)
|
7 (7.95)
|
46 (52.27)
|
|
Baseline cytopenia
| | | |
|
No
|
117 (11.52)
|
80 (7.87)
|
819 (80.61)
|
|
Yes
|
50 (15.06)
|
33 (9.94)
|
249 (75.00)
|
- Absolute numbers and percentages of failures, suboptimal and optimal collections, according to the presence of different risk factors in 1,348 newly diagnosed myeloma patients. Failure: CD34+ PBSC <2 × 106/kg; Suboptimal: CD34+ PBSC >2 and <5 × 106/kg; Optimal: CD34+ PBSC >5 × 106/kg. PBSC, peripheral blood stem cells.
